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Abstract: Over the past decade intrinsically disordered proteins (IDPs) have emerged as a biologically
important class of proteins, many of which are of therapeutic relevance. Here, we investigated
the interactions between a model IDP system, tau K18, and nine literature compounds that have
been reported as having an effect on tau in order to identify a robust IDP–ligand system for the
optimization of a range of biophysical methods. We used NMR, surface plasmon resonance (SPR)
and microscale thermophoresis (MST) methods to investigate the binding of these compounds to
tau K18; only one showed unambiguous interaction with tau K18. Several near neighbors of this
compound were synthesized and their interactions with tau K18 characterized using additional NMR
methods, including 1D ligand-observed NMR, diffusion-ordered spectroscopy (DOSY) and 19F NMR.
This study demonstrates that it is possible to detect and characterize IDP–ligand interactions using
biophysical methods. However, care must be taken to account for possible artefacts, particularly the
impact of compound solubility and where the protein has to be immobilized.
Keywords: intrinsically disordered protein; tau K18; nuclear magnetic resonance; surface plasmon
resonance; microscale thermophoresis
1. Introduction
The classical view of proteins has closely related function to a stable three-dimensional (3D)
structure and the paradigm of “Sequence→ Structure→ Function” has dominated scientific thinking
since early in the 20th century [1,2]. By the time the first experimentally derived 3D models of protein
structure were available, this “Structure→ Function” relationship was widely accepted and underpins
our understanding and appreciation of most protein structures [3,4]. It was in 1975 that the first ideas
of peptides and proteins (glucagon), having a biological function without having a defined structure,
emerged [5]. Since then, multiple proteins have been identified to be either completely disordered,
or have disordered regions [6,7].
The importance of the biological role and function of partially or fully disordered proteins has
grown in recent years, leading to an increasing interest in discovery of compounds to affect the
behaviour of IDPs in a potentially therapeutic manner. However, the identification and characterization
of IDP–ligand interactions has been challenging [8–10].
The aggregation-prone tau protein has been identified to be disordered and is involved in multiple
tauopathies, including Pick’s disease, frontotemporal dementia Parkinsonism linked to chromosome
17 (FTDP-17), progressive supranuclear palsy and Alzheimer’s disease [11–14]. With an increasingly
aging population, the number of people affected by Alzheimer’s disorder will increase, and together
with it, the therapeutic relevance of dementia-related targets, such as tau protein [15]. Tau aggregates,
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found in brain tissue, exhibit increased levels of phosphorylation and mostly contain double helical
stacks, or paired helical filaments (PHFs) [16]. It has also been demonstrated that two hexapeptide
motifs PHF6(VQIVYK) and PHF6*(VQIINK) play an important role in the formation of PHFs and
are found at the core of formed fibrils [17–19]. These motifs are located in imperfect repeat regions
R, namely in 2R and 3R, of the microtubule-binding domain. In addition to this, the formation of
fibrils appears to be enhanced by oxidation of Cys residues and interactions of tau with polyanionic
molecules in vitro, such as heparin [20,21].
To date, a range of molecules have been identified as modulators of the tau aggregation process
and state, including polyphenols, rhodanines, benzothiazoles, and phenothiazines, typically using
thioflavin-dye based assayswith limitedbiophysical characterization [22–32]. Because of the importance
of PHF6 and PHF6* regions in fibril formation, tau K18 and tau K19 constructs, containing 4 or 3 repeat
regions, respectively, have been used extensively as model systems in order to identify and evaluate
low molecular weight inhibitors of aggregation [19]. However, the interactions between tau and these
ligands have not been extensively characterized with widely used biophysical methods.
Here, we have used a range of biophysical techniques in order to characterize and explore the
interactions between monomeric tau K18 and several literature ligands. The experience gained through
these studies, in particular an understanding of possible sources for artefacts, will help in the application
of the repertoire of biophysical methods to study IDP–ligand interactions. The development and
optimisation of these methods may help to enable drug discovery campaigns against IDPs.
2. Results
2.1. Protein Production
Tau K18 forms aggregates in solution over time, associated with intermolecular cysteine
coupling [20]. Mutation of C291 andC322 to serine (C291S, C322S) is known to increase stability, while it
is claimed that the mutant protein maintains similar interactions. A construct for tau K18 (C291S,
C322S), hereafter tau K18M, was expressed and purified as previously described [33]. The biotinylation
of AviTag-tau K18M using BirA enzyme and incorporation of 3-fluoro Tyr as Y310 to tau K18M were
achieved following previously published methods [34,35].
2.2. NMR Identifies Cl-NQTrp to Interact with Monomeric tau K18M
The aqueous solubility of nine tau ligands were evaluated with 1D 1HNMR by measuring the
integral of a specific peak for the ligand while increasing its concentration to the point where the signal
failed to increase linearly (Figure 1A,B). The soluble ligands were then screened against monomeric
15N-labeled tau K18M using 2D SF-HMQC pulse sequence which produces spectra that are used to
detect changes to the backbone amide signals (Figure 1C, Figure S1) [36]. It was determined that only
compound 6 (Cl-NQTrp) produced significant chemical shift perturbations (CSPs), mainly affecting
the PHF6 region. The 2D [1H-13C] HSQC spectrum indicated that the easily distinguishable side
chains of aromatic residues of tau K18M were also affected by compound 6 (Y310 and F346) (Figure S2).
CSPs were defined as significant if the shift was more than half of a peak width and dose-dependent.
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Figure 1. Literature ligand NMR titration assay against tau K18M. (A) Chemical structures of the
ligands (CPK colouring scheme). (B) An example of 1D 1H NMR spectra during titration of Cl-NQTrp
and ID220255 as determined by 1D 1H NMR with determined ligand solubilities. (C) The 2D [1H-15N]
SF-HMQC spectra of a non-binder ID220149 (2 mM) (Left) and a binder Cl-NQTrp (2 mM) (Right).
2.3. SPR and MST Identifies Additional Compounds to Interact with tau K18M
Biotinylated AviTag-tau K18M was immobilized on a streptavidin-derivatized dextran surface for
SPR experiments. A dose–response titration assay identified Methylene Blue, PHF016, and Cl-NQTrp
as interacting (Figures 2A and S3). ID220149 exhibited lower than theoretical Rmax (~23 RU) responses
and was considered to be a potential artefact (Figure S3). The Methylene Blue SPR kinetic curves
indicated potential non-specific interactions with the immobilized protein on the surface at higher
concentrations (>150 µM). The partially saturating steady-state binding profile was used to calculate
KD value of 159 +/− 9 µM. PHF016 showed slow-on, slow-off behaviour with linear dose–response
curve with no saturation above determined theoretical Rmax, indicating non-stoichiometric interactions.
Cl-NQTrp, (shown to interact with tau K18M byNMR), interactedwith the protein in non-stoichiometric
manner at higher concentrations (>1 mM). bb14 did not interact with tau K18 to any detectable extent.
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Figure 2. Surface plasmon resonance (SPR) and microscale thermophoresis (MST) techniques were
used to assess ligand binding to tau K18M. (A) Kinetic SPR binding curves and steady-state affinity
graphs for Methylene Blue, Cl-NQTrp, PHF016 and bb14 with calculated KD values. Red-circled
data point marks excluded data. Immobilization level: 1000 RU of biotinylated AviTag-tau K18M.
(B) Methylene Blue, Cl-NQTrp, PHF016 and bb14 MST dose–response data with assessed KD or EC50
values to tau K18M.
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The overlap of the spectrum of intrinsic fluorescence of Methylene Blue and RED-Tris-NTA dye
at λ = 600–650 nm prevented the direct labeling of the protein with the dye for MST experiments.
However, a label-free approach was possible. Tau K18M was titrated from 5.9 to 2000 nM onto 100 nM
of Methylene Blue and an EC50 of 50 +/− 4 nM was determined with Hill coefficient of 4 (Figure 2B).
The data could not be fitted to a standard 1:1 model suggesting that multiple molecules may interact
with the protein at the same time.
For other MST experiments, tau K18M was labeled with RED-Tris-NTA dye. The MST data for
Cl-NQTrp suggested that the ligand interacted with tau K18M in a dose-dependent manner, confirming
the results reported above with NMR and SPR (Figures 2B and S4). The affinity of Cl-NQTrp could not
be reliably determined because the MST data did not reach saturation. While compound 2 (PHF016)
data could not be fitted to a binding model, compound 5 (bb14) was identified to interact with the
labeled protein with a KD of 73 +/− 23 µM (1:1 binding model).
2.4. Detailed Characterization of Cl-NQTrp and Its Interactions with tau K18M
Cl-NQTrp contains electrophilic quinone and chloro-enone groups; HPLC-MS and NMR
experiments confirmed that the compound does not form covalent adducts with tau K18M or
dithiothreitol (DTT) (Figure S5). The IDP–ligand interactions were also determined to be not
non-specific or solely electrostatic in nature, as CSPs remained of comparable magnitude at
increasing NaCl concentrations, and no interactions were observed with a fragment of Cl-NQTrp,
L-Trp (Figures S6 and S7).
To further explore the SAR for compound binding, eight near-neighbors (NNs) of Cl-NQTrp were
synthesized (Figure 3A). All NNs were observed to produce similar CSPs in 2D [1H-15N] SF-HMQC
spectra (Figure S8). Interestingly, tau K18M formed a precipitate at higher concentrations of NNs
(>2 mM), particularly with 6E and 6G (>1 mM) (Figure S9). This effect was not due to limiting
compound solubility.
Three widely used ligand-observed NMR methods were used to assess Cl-NQTrp interactions
with tau K18M. These are the saturation transfer difference (STD) experiment which utilizes direct
magnetization transfer from protein to bound ligand [37], the water–ligand observed via gradient
spectroscopy (water-LOGSY) experiment [38] which detects phase-sensitive NOE transfer from water
molecules to both free and bound ligands, and a T2 relaxation-filtered experiment which identifies
small molecules which show rapid T2 relaxation [39]; this rapid T2 relaxation (short T2 relaxation time)
is typically the result of interactions between the ligand and a slowly-tumbling protein.
No signal indicative of binding was observed in STD data acquired for the tau K18M–Cl-NQTrp
complex (Figure 3B). Water-LOGSY data indicated that Cl-NQTrp interacts with tau K18M, particularly
for compound 6D (Figure 3C). Interestingly, compound 6D exhibited a short T2 relaxation time using
standard relaxation delays in the 1H T2-filtered experiment even when the tau K18M sample was not
present (Figure 3D). However, this rapid T2 relaxation was both unchanged over a wide range of ligand
concentrations and also in the presence of 0.2% Tween-20, indicating that the T2 relaxation observed is
due to intramolecular rather than intermolecular interactions (Figure 3E, Figure S10, Table S2).
In order to account for the observed short T2 relaxation times and to evaluate T2 relaxation for
Cl-NQTrp and its NNs more accurately, extensive 1H Carr–Purcell–Meiboom–Gill (CPMG)-filtered
experiments were performed in the absence and presence of tau K18M. The readily assigned tryptophan
methylene protons were used to track the changes in T2 relaxation time of eachmolecule under different
conditions (Figure 3E, Table S2). While the T2 values were comparable for Cl-NQTrp and its NNs at 0.1
and 1 mM without protein present, the values decreased in the presence of tau K18M, consistent with
an interaction between the ligand and IDP, as the rapidly tumbling ligand moves more slowly upon
binding to a slowly-tumbling protein. Such data outcome agrees with our previous observations by 2D
[1H-15N] SF-HMQC and water-LOGSY (Figures 1C and 3C). Additionally, T2 relaxation times for the
methylene protons of L-Trp were measured as being one order of magnitude longer than for Cl-NQTrp,
indicating that short T2 values observed for Cl-NQTrp are compound-specific (Figure 3E, Table S2).
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Figure 3. 1D ligand-observed NMR studies with Cl-NQTrp and its near neighbors (NNs).
(A) Synthesized NNs of Cl-NQTrp. (B) Saturation transfer difference (STD) data (red) indicates
no ligand-specific signals when compared to 1H reference spectrum (blue) for compound 6D.
(C)Water–ligand observed via gradient spectroscopy (water-LOGSY) data (red) indicates ligand-specific
peaks (black arrows) when compared to a 1H reference spectrum (blue) for compound 6D.
(D) 1H Carr–Purcell–Meiboom–Gill (CPMG)-filtered data for compound 6D in the absence (D.1) and
presence (D.2) of tau K18M (protein-derived peaks marked as ∗) indicates no IDP–ligand interactions
using standard (200ms) relaxation delays as ligand-specific peaks (black arrows) decreased in intensity
at a similar level after CPMG filter. (E) Comparison of T2 relaxation times for tryptophan methylene
group (red circled) at different concentrations of compound 6 and its NNs in the presence or absence of
tau K18M. L-Trp T2 relaxation times were measured without any protein present. (F) 1H NMR spectral
changes for red-circled proton of Cl-NQTrp indicating decreasing intensity, coalescence, splitting,
and sharpening of the signal with decreasing temperature indicating intermediate chemical exchange
events (Left). Over a 1 µs simulation in explicit water, Cl-NQTrp adopts either folded or unfolded
conformation close to 50% of the time (Right). Atom pair distance: 4 to 8 Å between the red-circled
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Temperature gradient experiments were performed from 278 K to 318 K for Cl-NQTrp.
These indicated intermediate chemical exchange events which may contribute to the observed
short T2 relaxation times observed earlier (Figure 3D,E,F). The exchange events can be observed
as ligand-specific peaks in the 1D 1H spectrum decrease in intensity, coalesce, split, and sharpen
again with decreasing temperature. This may result in part from exchange between stacked and
non-stacked indole:napthoquinone conformations, which causes a significant change in the local
chemical environment on the NMR time scale as predicted by molecular dynamics simulation
(Figure 3F).
It was hypothesized that Cl-NQTrp and its NNs may also affect the diffusion rate D of tau K18M
at concentrations below those which resulted in precipitation. Diffusion ordered spectroscopy (DOSY)
measures D value for individual NMR resonances, identifying any changes to the diffusion rate of the
ligand as it interacts with the target protein, and vice versa [40,41]. DOSY data indicated a small but
potentially significant change in D value for tau K18M, particularly in the presence of compound 6C
(Figure 4A).

 
Figure 4. Investigating tau K18M and Cl-NQTrp interactions using diffusion-ordered spectroscopy
(DOSY) and 19F NMR. (A) The determination of diffusion rate D for 50 µM tau K18M in the presence of
different concentrations of compound 6C. (B) 19F NMR spectra for 50 µM tau K18M (3-fluoro-Y310)
and the observed chemical shift perturbations (CSPs) in the presence of compound 6D. Black arrow
denote the vector direction of CSPs.
The 19F nucleus is highly sensitive to its local chemical environment [42]. Since one of the
affected amino acid residues was Y310, as indicated by 2D [1H-15N] SF-HMQC and [1H-13C] HSQC
spectra (Figure 1, Figure S1, Figure S2), 19F NMR was used to probe the IDP–ligand interactions using
fluorine-labeled tau K18M (3-fluoro-Y310) and detect CSPs caused by the ligand. However, 19F NMR
data showed only small CSPs in the presence of compound 6D with a non-saturating dose response
profile (Figure 4B).
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3. Discussion
Recent research has identified a number of therapeutically relevant intrinsically disorderedproteins
(IDPs), leading to growing interest in identifying small molecules which affect their function [6,7].
However, due to the disordered nature of IDPs, it is necessary to establish and optimize reliable
experimental protocols for biophysical methods to characterize IDP–ligand interactions. In order to do
this, we have studied the interaction of a model tau system with a range of available ligands from
literature studies using a suite of widely used biophysical techniques.
Tau protein is an IDP whose aggregation has been linked to multiple tauopathies [11–14].
While many tau aggregation inhibitors have been identified, there is limited experimental evidence
for these compounds interacting with tau [22–32] and no broad studies applying a consistent set of
methods. Methylene Blue and BSc3094 have been shown previously to interact with native tau K18
using 2D HSQC and 1D STD NMR methods, mapping the perturbed backbone amides and ligand
protons, respectively.
It has been reported that capping or mutating Cys residues inhibits the aggregation of wild-type
tau K18 [43]. In order to improve the stability of the protein over time during lengthyNMR experiments,
we mutated Cys to Ser to increase the stability of tau K18M while maintaining similar intramolecular
and intermolecular interactions.
Typically, 1D NMR screening methods, such as STD, wLOGSY and CPMG-filtered, are used as a
primary screening step in order to identify and prioritize binders from a compound library [37–39,44].
Following the identification of potent ligands, 2D [1H-15N] HSQC NMR can then be used to map a
potential binding site. If the compound is of sufficient solubility, 2D HSQC NMR is considered to be a
“gold standard” for detecting and characterizing protein–ligand interactions as the spectra identify
specific backbone amides of the protein that are perturbed on ligand binding. The 2D SOFAST-HMQC
(SF-HMQC) experiment is a rapid alternative to the conventional HSQC technique, and is particularly
well suited for screening interactions with IDPs due to lack of dispersion in the amide region of the
IDP spectrum compared to a typical folded protein [36].
Since this study was designed to robustly identify a model IDP–ligand system, and then to
investigate the application of biophysical methods to this system, the “gold standard” 2D SF-HMQC
experiment was used as a primary screen in order to identify a validated intermolecular interaction.
Further, close near-neighbors of the ligand identified by 2D SF-HMQC were synthesized in order to
ensure that the observed perturbations were not simply artefacts resulting from a contaminant in the
original screening sample as has been reported previously [45].
The nine tau ligands screened are all commercially available and have been reported to modulate
tau activity [24–32]. The titration experimentswere performed in the presence ofmonomeric form of tau
K18M. Only Cl-NQTrp appeared to bind robustly to this model IDP (Figures 1 and S1). Other ligands
may interact with the oligomeric rather than monomeric form of tau K18, as suggested previously [23];
such compounds would not have been identified by this screening cascade, which was designed solely
to identify a ligand for monomeric tau K18. The compounds ID220255 and ID220149, for example, have
been detected to bind to wild-type full length tau protein via high-throughput chemical microarray
SPR (HT-CM-SPR) imaging screen and to also inhibit tau aggregation [28]. The same ligands were
also identified to inhibit the aggregation of wild-type tau K18, indicating that the interactions between
ligand and protein are occurring in the wild-type tau K18 part of the protein. As Methylene Blue has
been shown to oxidize Cys residues of tau protein, the C291S and C322S mutations present in the tau
K18 construct used here may have impaired the binding of Methylene Blue compared to previous
NMR studies [25].
While Methylene Blue, bb14, and PHF016 were identified to interact with tau K18M by MST
or SPR, but not by 2D [1H-15N] SF-HMQC, it is possible that such data are not representative
due to immobilization of the IDP on the dextran surface or the use of dye-labeling (Figure 2).
Any conformational restrictions of an IDP may cause the protein to assume a physiologically irrelevant
conformation, causing artefactual results. The SPR angle shifts and the observed responses have been
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previously shown to be sensitive to changes of pH, ionic strength and conformation of the immobilized
protein [46,47]. While immobilized folded proteins can maintain their rigidity and interact with
ligands, the structure of IDPs is likely to be perturbed upon interaction with a ligand due to their
dynamic structure.
Methylene Blue did not show any apparent interaction with tau K18M in 2D [1H-15N] SF-HMQC
NMR spectra (Figure 1), whereas an interaction was identified by MST (KD 50 +/− 4 nM) (Figure 2).
Previously, it has been reported that Methylene Blue interacts with wild type tau K18(C291,C322) with
a KD of 125.8 +/− 5.4 nM, as determined by MST [48], which is broadly consistent with the value
determined in our study. Previous investigations of wild type tau K18 have also suggested that the
Cys residues may be involved in binding Methylene Blue [25,48]. However, our MST results using
mutated tau K18 (tau K18M), which lacks these Cys residues, showed a similar interaction suggesting
that the Cys residues are not critical. However, it is possible that non-specific or indirect interactions
between the compound and dye-labeled tau may give rise to artefactual results in MST, particularly
since in our studies no interaction is observed by NMR.
Electron-rich quinone and chloro-enone chemical groups, as are present in Cl-NQTrp, belong to
the pan-assay interference (PAINS) group of moieties which can give rise to false positives in a wide
range of assays, specifically by interfering with colorimetric readout or by forming covalent adducts
with proteins [49]. The MS study showed no indication of covalently bound ligand to the protein,
ruling out covalent modification of tau K18M as a mode-of-action (Figure S5).
Limited SAR has shown that NNs produce similar CSPs to the parent molecule Cl-NQTrp when
interacting with tau K18M (Figures 3A and S8). Of the 1D ligand-observed NMR methods, only 1H
water-LOGSY and 1H CPMG-filtered experiments detected the binding of Cl-NQTrp and NNs to tau
K18M; this is particularly evident for compound 6D (Figure 3C,E). The STD experiment relies upon
saturation of nuclei in the hydrophobic core of a protein; this saturation spreads across the protein
via through-space coupling, and is subsequently transferred to a bound ligand in the same manner.
The lack of STD signal for binding of Cl-NQTrp to tau K18M may simply be due to the lack of an
intact hydrophobic core in the protein [37], but may also result from the lack of persistent protein
structure through which magnetization can be transferred to reach any ligand binding site. In contrast,
water-LOGSY, which does report an interaction between Cl-NQTrp and tau K18M, does not require the
presence of a folded structure since magnetization is transferred from water molecules to the ligand
via protein–ligand or protein–ligand–water complexes [38].
Initial CPMG-filtered experiments using standard T2 relaxation delays did not indicate any
Cl-NQTrp–tau K18M interactions (Figure 3(D.1,D.2)). However, this was found to potentially be
due to the unusually short T2 relaxation time of Cl-NQTrp itself. Therefore, shorter T2 delays were
used to further probe protein–ligand interactions and the acquired data was consistent with binding
(Figure 3C). The observed short T2 relaxation times were attributed to the intramolecular chemical
exchange events rather than aggregate formation, since the T2 relaxation time did not change upon
addition of a detergent and the T2 relaxation time is invariant with ligand concentration [39,50]. The
chemical exchange appears to occur when Cl-NQTrp molecule changes between “open” and “closed”
conformations of the indole and napthoquinone groups as identified through molecular dynamics
(Figure 3F).
The diffusion rate D of tau K18M is affected slightly (<5%), particularly in the presence of
compound 6C (Figure 4A). It is not clear, however, whether this change is significant and indeed
whether this change results directly from a ligand binding event. Previous investigation of bovine
pancreatic trypsin inhibitor (BPTI) has shown that the 58 amino acid long fully unfolded peptide has
13 to 20% lower diffusion rate than partially folded peptide [41]. Interestingly, compounds 6E and 6G
cause tau K18M to precipitate out of solution at >1 mM, which is not related to limiting compound
solubility (Figure S9). The precipitation phenomenon did not cause any observable change in diffusion
rate D and 2D [1H-15N] SF-HMQC spectra. As NMR DOSY can only measure diffusion of soluble
components, any diffusion changes for insoluble components cannot be evaluated. It is possible that
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the structural changes caused by ligand binding would need to be both large enough and to not cause
precipitation of the target protein in order to observe changes in diffusion rate. In addition to this, such
change would potentially be observable in 2D [1H-15N] SF-HMQC spectra as the system becomes more
ordered. It would be of interest to further investigate diffusion changes using more precise methods.
As 19FNMRchemical shifts are sensitive to the local environment [42], specific fluorine labelingwas
used to probe tau K18M–Cl-NQTrp interactions. The chemical shifts of tau K18M Y310 were perturbed
by compound 6D in 2D [1H-15N] SF-HMQC spectra. Similar perturbations were also observed for
Y(3-fluoro)310 in 19F NMR spectra, but these were of relatively small magnitude (Figure 4B). This is
somewhat surprising given the sensitivity of the 19F nucleus. However, prediction of 19F chemical
shift perturbation remains challenging [51] and it is possible that the relatively small shifts observed
are a result of several distinct processes, of which ligand binding may be one.
Due to the low affinity of the interaction between tau K18M and Cl-NQTrp, determination of
more detailed structural data remains a challenge. However, the study of tau K18M and Cl-NQTrp
interactions indicates that NMR may be one of the least artefact-prone and most robust techniques
for characterizing such IDP–ligand interactions, provided the tested compounds exhibit satisfactory
solubility profiles. SPR and MST methods also provide orthogonal approaches, allowing the use
of limited solubility compounds, although the amount of structural data obtained may be limited.
Furthermore, these studies highlight that care must be taken when interpreting biophysical data
relating to low affinity and transient interactions, and that while a simple interpretation of a single
result is not always possible the careful use of orthogonal experiments and techniques can provide a
robust characterization of an IDP–ligand interaction.
4. Materials and Methods
4.1. Materials
Initial batch of 15N-labeled 6xHis-tau K18(C291S, C322S), or tau K18M, and 9 literature compounds
were kindly provided by Servier (Paris, France). All reagents and solvents were obtained from
commercial vendors unless stated otherwise.
4.2. Protein Expression and Purification
Codon-optimized genes were ordered fromGenScript (Piscataway, NJ, USA) in pET24a expression
vector with NdeI and XhoI restriction sites. Protein concentrations were determined using Pierce
BCA assay kit (Thermofisher Scientific, Vilnius, Lithuania). Protein intact mass was determined using
HPLC-MS (Agilent, Santa Clara, CA, USA) (Supplementary Data). Protein purification was performed
using AKTA FPLC system (GE Healthcare, Uppsala, Sweden).
4.2.1. 6xHis-tau K18(C291S, C322S)
The protein-coding plasmid was transformed to E. coli BL21(DE3) cells and cultured at 37 ◦C
in flasks containing Luria–Bertani (LB) with 50 µg/mL kanamycin. The expression was induced at
OD600 = 0.8 with 1 mM final concentration of IPTG for 4 h at 37 ◦C. After expression, the cells were
pelleted at 5000× g for 20 min and stored at −80 ◦C. For producing protein for NMR studies, M9 media
supplemented with [13C] D-glucose (2 g/L) and/or 15NH4Cl (1 g/L) was used.
Cell pellets were resuspended in ice-cold lysis buffer (50 mM NaPi pH 7.5, 500 mM NaCl, 10 mM
imidazole), supplemented with cOmplete Protease Inhibitor Cocktail EDTA-free tablets, and lysed
using French press homogenization system (Homogenising Systems Limited, Stansted, UK). The lysate
was then incubated at 90 ◦C for 15 min under mild stirring. Following this, the lysate was cooled down
in ice bath for 10 min and further clarified by centrifugation at 40,000× g for 1 h. The supernatant
was loaded onto a 1 mL HisTrap FF column (GE Healthcare) equilibrated with 25 mMNaPi pH 7.5,
500 mMNaCl, 10 mM imidazole and the protein was eluted using a 3-step gradient (5, 20 and 100%) of
25 mM NaPi pH 7.5, 500 mM NaCl, 500 mM imidazole. Fractions containing the protein were desalted
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to 25 mM NaPi pH 7.0, 25 mM NaCl, 1 mM EDTA using HiPrep Desalt 26/10 column and loaded
onto pre-equilibrated with desalting buffer 5 mL HiTrap SP FF column. The protein was eluted with
gradient over 10 CV from 0 to 100% of 25 mMNaPi pH 7.0, 1 M NaCl, 1 mM EDTA. Protein-containing
fractions were further purified using HiPrep Superdex 16/60 75 PG column in 25 mM NaPi pH 6.6,
150 mM NaCl, 0.1 mM EDTA, snapfrozen in liquid N2 and stored at −80 ◦C.
4.2.2. 6xHis-TEV-AviTag-tau K18(C291S, C322S)
The protein was expressed as described for non-labeled tau K18M construct. After this, the protein
was purified using the same protocol as for non-labeled protein until after the elution from HisTrap
FF column. Protein-containing fractions were then desalted to 25 mM NaPi pH 7.5, 500 mM NaCl,
10 mM imidazole using HiPrep 26/10 column. The sample was supplemented with 2.5 mg of TEV
protease (in-house) and incubated at 4 ◦C overnight. After incubation, the sample was further purified
by loading the mixture on 1 mL HisTrap FF column in 25 mM NaPi pH 7.5, 500 mM NaCl, 10 mM.
After eluting the protein with 3 step-gradient (5, 20, 100%) of 25 mM NaPi pH 7.5, 500 mM NaCl,
500 mM imidazole, cleaved protein-containing fractions were further purified using HiPrep Superdex
16/60 75 PG column in 25 mMNaPi pH 6.6, 150 mMNaCl. The pure protein samples were then pooled,
desalted to 50 mM bicine pH 8.3 and had its concentration adjusted to 40 µM. This was followed
by the addition of final concentration of 10 mM ATP, 100 µM D-biotin, 10 mM MgCl2, and 5 µg of
BirA (in-house) (per 10 nmol of AviTag-tau K18(C291S, C322S). The mixture was incubated at room
temperature for 2 h and biotinylation efficiency was determined by HPLC-MS. After biotinylation,
the sample was further purified using HiPrep Superdex 16/60 75 PG, pre-equilibrated with 25 mM
NaPi pH 6.6, 150 mM NaCl, snapfrozen in liquid N2 and stored at −80 ◦C.
4.3. Compound Synthesis
(2S)-2-[(3-chloro-1,4-dioxonaphthalen-2-yl)amino]-3-(1H-indol-3-yl)propanoic acid (Cl-NQTrp)
and its near-neighbors (NNs) were synthesized using adapted one-step synthesis protocol [52].
Compound purity and structural integrity was assessed using 1H NMR and HPLC-MS
(Supplementary Data).
4.4. Nuclear Magnetic Resonance
Protein and ligandNMRdata were obtained using Bruker AVANCE 600MHz spectrometer(Bruker
BioSpin, Fällanden, Switzerland) equipped with a BACS-120 sample changer and QCI-F cryoprobe
in 50 mM NaPi pH 6.6, 25 mM NaCl, 100 µM DSS, 5% D2O, 4% d6-DMSO at 298 K, unless stated
otherwise. Bruker DPX-400 spectrometer (Bruker BioSpin, Fällanden, Switzerland) was used to assess
structural integrity of organic compounds in d6-DMSO at 298 K. The NMR data were processed
and analyzed using TopSpin 4.0.2 (Bruker BioSpin, Fällanden, Switzerland), MNova 11.0 (MestreLab
Research, Santiago de Compostela, Spain) and Dynamics Center 2.5.4 (Bruker BioSpin, Fällanden,
Switzerland). Experimental NMR parameters can be found in Table S1.
4.5. Surface Plasmon Resonance
Immobilization of target protein was performed in 50 mM HEPES pH 7.4, 150 mM NaCl,
0.05% Tween-20 at 20 ◦C using Biacore T200 (GEHealthcare, Uppsala, Sweden). For biotin-SA coupling,
the surface of S Series Sensor Chip SA (GE Healthcare, Uppsala, Sweden) was first conditioned with
three consecutive 1 min injections of 1 M NaCl + 50 mM NaOH at 10 µL/min. This was followed
by injection of 100 nM of biotinylated protein at 5 µL/min until immobilization level of 1000 RU.
Eight startup cycles were used for stabilizing the surface after the immobilization.
Single-cycle kinetics experiments were performed as 1:1 serial dilution concentrations of the
ligands with 45 s association and 60 s dissociation times at 30 µL/min at 20 ◦C in 50 mMHEPES pH 7.4,
150 mM NaCl, 0.05% Tween-20, 4% DMSO. The ligand concentrations used were based on solubility
studies by NMR and literature data. Blank injections were also used for double referencing. Solvent
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correction was performed with 8 point samples at from 3.5 to 4.8% DMSO. The flow system was
washed with 50% DMSO after each cycle.
Theoretical Rmax was calculated using the following formula:
Rmax =
Immobilization level o f target protein (RU)
MW o f immobilized protein (Da)
∗MW o f ligand (Da) ∗ 1(valency)
Experimental data was analyzed using Biacore Insight Evaluation Software (GE Healthcare,
Uppsala, Sweden) and SimFit (https://www.simfit.org.uk/).
4.6. Microscale Thermophoresis
The experiments were performed on Monolith NT Automated (NanoTemper, Munich, Germany)
machine with the following parameters:
• MST power = 40%
• Excitation power = 15%
• Temperature = 20 ◦C
• Acquisition mode = Pico-Red
The data was processed using MO.Affinity analysis v2.2.4 (NanoTemper). The change in
fluorescence was used to fit the data to either 1:1 KD model or Hills equation.
For protein–ligand interaction measurements using dye labeling, 6xHis-tagged protein was
labeled with RED-Tris dye following manufacturer’s protocol. Following this, an appropriate number
of the labeled protein samples with the ligand were prepared by mixing 1 µL of ligand in 100%
DMSO with 24 µL of labeled protein in 50 mM HEPES pH 7.4, 150 mM NaCl, 0.05% Tween 20.
Final DMSO concentration = 4%. The samples were incubated for 30 min, loaded into premium-coated
capillaries and measured. The ligand concentrations used were based on solubility studies by NMR
and literature data
For non-labeled approach, 24 samples of tau K18M were prepared from 5.9 to 1000 nM as
1.25× dilutions in the presence of 100 nM of compound 1 (Methylene Blue) in 50 mM HEPES pH 7.4,
150 mM NaCl, 0.05% Tween 20, 4% DMSO.
4.7. Molecular Dynamics
The simulation system of Cl-NQTrpwas prepared as follows. To prepare Cl-NQTrp, the compound
titratable groups were assigned standard protonation states at pH = 7 and the 2D to 3D conversion was
done by MacroModel [53]. After that, the simulation system of Cl-NQTrp was built with the Maestro
graphical user interface designed for Desmond [54], distributed by Schrödinger tools (Schrödinger,
New York, NY, USA). The default setup parameters were kept which used the NPT ensemble with
explicit SPC waters and added counterions to neutralize the overall charge of the system.
The MD was performed by Desmond at constant temperature (300 K) and pressure (1.01 bar),
and coordinates saved every 4.8 picoseconds, keeping the default settings. The OPLS3 force-field was
used [55]. Cl-NQTrp was simulated for 1.0 µs free in aqueous solution. To analyze the simulation
results, the snapshots were extracted from Cl-NQTrp MD with the Schrödinger tools.
5. Conclusions
We have characterized the interaction of a literature ligand, Cl-NQTrp, with the model IDP tau
K18M, using a range of biophysical techniques including protein- and ligand-observed NMR, SPR,
and MST. Close near neighbors of the Cl-NQTrp parent compound were synthesized and observed
to bind to the same site in tau K18M with a range of affinities. The studies identified issues with the
applicability and artefacts with all biophysical methods used. While NMR proved the most detailed
and robust data about IDP–ligand interactions, complementary biophysical methods, such as SPR and
Int. J. Mol. Sci. 2020, 21, 5257 12 of 15
MST, should be used, particularly if compound solubility is limited. Additional studies would be
necessary for a more complete structural characterization of the interactions in the tau K18M–Cl-NQTrp.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/15/5257/s1,
Figure S1: 2D [1H-15N] SF-HMQC spectra of 15N-labelled tau K18M in the presence and absence of literature
compounds, Figure S2: 2D [1H-13C] HSQC spectra of 13C,15N-labelled tau K18M in the presence and absence of
compound 6, Figure S3: Kinetic SPR binding curves and steady-state affinity graphs for literature compounds,
Figure S3: Kinetic SPR binding curves and steady-state affinity graphs for literature compounds, Figure S4:
MST dose-response data for literature compounds to dye-labelled tau K18M, Figure S5: Investigation of potential
Cl-NQTrp covalent adducts to tau K18M using MS and NMR, Figure S6: 2D [1H-15N] SF-HMQC spectra of 15N
tau K18M in the presence of 2 mM Cl-NQTrp at different concentrations of NaCl., Figure S7. The observed CSPs
for 15N tau K18M in the presence of ethanolamine, acetic.
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